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mRNA editingAPOBEC-1 Complementation Factor (ACF) is an RNA-binding protein that interacts with apoB mRNA to
support RNA editing. ACF trafﬁcs between the cytoplasm and nucleus. It is retained in the nucleus in
response to elevated serum insulin levels where it supports enhanced apoB mRNA editing. In this report we
tested whether ACF may have the ability to regulate nuclear export of apoB mRNA to the sites of translation
in the cytoplasm. Using mouse models of obesity-induced insulin resistance and primary hepatocyte cultures
we demonstrated that both nuclear retention of ACF and apoB mRNA editing were reduced in the livers of
hyperinsulinemic obese mice relative to lean controls. Coincident with an increase in the recovery of ACF in
the cytoplasm was an increase in the proportion of total cellular apoB mRNA recovered in cytoplasmic
extracts. Cytoplasmic ACF from both lean controls and obese mouse livers was enriched in endosomal
fractions associated with apoB mRNA translation and ApoB lipoprotein assembly. Inhibition of ACF export to
the cytoplasm resulted in nuclear retention of apoB mRNA and reduced both intracellular and secreted ApoB
protein in primary hepatocytes. The importance of ACF for modulating ApoB was supported by the ﬁnding
that RNAi knockdown of ACF reduced ApoB secretion. An additional discovery from this study was the
ﬁnding that leptin is a suppressor ACF expression. Dyslipidemia is a common pathology associated with
insulin resistance that is in part due to the loss of insulin controlled secretion of lipid in ApoB-containing very
low density lipoproteins. The data from animal models suggested that loss of insulin regulated ACF
trafﬁcking and leptin regulated ACF expression may make an early contribution to the overall pathology
associated with very low density lipoprotein secretion from the liver in obese individuals.ctor; ApoB, Apolipoprotein B;
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ACF (APOBEC-1 Complementation Factor) is a member of the
ELAV/Hu family of RNA-binding proteins, characterized by their
multiple RNA Recognition Motifs (RRMs) [1]. This family of proteinsfunctions by controlling the stability of AU-rich RNA [2]. ACF contains
3 RRMs in its N-terminus and has a nanomolar afﬁnity [3] for an 11
nucleotide AU-rich ‘mooring’ sequence 3′ of the edited cytidine in
apoB mRNA [4,5]. ACF is a required factor for apoB mRNA editing site
recognition, [6,7] and recruitment of APOBEC-1, a cytidine deaminase,
to nucleotide C6666 for site-speciﬁc C to U editing [8]. This RNA
modiﬁcation enables two functional protein products to be expressed
from one gene [9,10] (ApoB100 and ApoB48) that serve as scaffold
proteins for lipoprotein particle assembly and transport of lipid from
the liver and small intestine. Editing of apoB mRNA is a characteristic
of differentiated tissue types [11] and is regulated hormonally [12]
and metabolically [13–18].
While APOBEC-1 and apoB mRNA editing are not essential for life
[19], ACF knockout was embryonically lethal [20]. ACF was essential at
the pre-implantation stage prior to the developmental induction of
apoB mRNA and apoB mRNA editing [21], and therefore ACF must
have had a biological function other than the complementation of
apoB mRNA editing. In this regard, ‘mooring’ sequences have been
identiﬁed in numerous mRNAs, some of which encode proteins
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there is an alternative function of ACF has been an open question
based on the ﬁnding that it is abundantly expressed in human liver
even though APOBEC-1 and editing activity are not observed in this
tissue.
ApoB mRNA editing occurred in the cell nucleus on a spliced
polyadenylated message [23,24]. Despite compartmentalization of
apoB editing, ACF is distributed throughout the cell and was recovered
from cell extracts as inactive 60S cytoplasmic complexes and active
27S nuclear editosomes [25]. ACF trafﬁcking from the cytoplasm into
the nucleus was dependent on an NLS (Nuclear Localization
Sequence) in the C-terminal half of the protein [26]. Increased nuclear
abundance of ACF correlated with increased editing efﬁciency
[12,17,27]. We recently reported that nuclear retention of ACF in
response to metabolic stimulation correlated with phosphorylation of
ACF's serine residue(s) by insulin-stimulated protein kinase C [27,28].
It was also observed that nuclear accumulation of ACF resulted from
the inhibition of Protein Phosphatase 1 (PP1), suggesting that ACF
export required de-phosphorylation. These ﬁndings were of interest
as immuno-electron microscopy of rat liver thin sections suggested
that cytoplasmic ACF was localized to the exterior surface of the
endoplasmic reticulum, the site of apoB translation [25]. The
localization of ACF with apoB translational complexes also was
supported by the ﬁnding that ACF was required to protect edited
apoB mRNA from Nonsense Mediated Decay (NMD) [29]. This led us
to the hypothesis that, in addition to mRNA editing, ACF may have a
function in the export of apoB mRNA from the nucleus to the
cytoplasm and its continued association with apoB mRNA may
modulate the availability of apoB mRNA for ApoB protein translation.
Evidence will be presented from studies in animal models for obesity
that the abundance and trafﬁcking of ACF were regulated processes
that affected ApoB protein expression.
2. Materials and methods
2.1. Animal care and primary hepatocyte preparation
Male B6.V-Lepob/J, B6.Cg-m Leprdb/++/J and C57Bl/6J mice were
obtained from Jackson Laboratories (Bar Harbor, ME) and were used
between 10 and 12 weeks of age, referred to herein as Ob/Ob, Db/Db,
and cogenic lean control (respectively). Animals were housed in
rooms with 12 h light/dark cycles and fed normal rodent chow. Blood
glucose levels were determined on blood drawn from the tail vein
using a Bayer glucometer and Ascensia Contour Diabetic Test Strips.
Fasting was conducted overnight for a 12 h period. Insulin intraper-
itoneal injections were conducted with 1.5 IU/kg Novolin® N (Novo
Nordisk, Princeton, NJ) and animals were sacriﬁced 4h following
injection. Primary mouse hepatocytes were harvested as described
previously [14]. Cells were plated in William's E Media (Sigma, St.
Louis, MO) with 5% FBS overnight prior to treatment on BIOCOAT type
I collagen coated dishes (Becton Dickinson Labware).
2.2. Subcellular fractionation
Whole liver extracts were prepared by Teﬂon to glass homog-
enization of liver in 0.25 STM (0.25 M sucrose, 50 mM Tris pH 7.0
and 5 mM MgCl2) supplemented with Complete Protease Inhibitors
(Roche, Indianapolis, IN) and phosphatase inhibitors, PhosStop
(Roche) then cleared at 3000×g for 10 min. Nuclear and cytoplas-
mic preparations were centrifuged as previously described [30] and
the quality of the separation was assessed by western blotting
extracts for cytoplasmic β-actin (Sigma) and nuclear histone H1
(Santa Cruz Biotechnology, Santa Cruz, CA). Sub-fractionation of
cytoplasmic extract into HDM, LDM, and residual cytoplasmic
fractions was conducted as previously described [31]. Subcellular
fractionation of primary rat hepatocytes was conducted using theNE-PER kit (Thermo Scientiﬁc, Waltman, MA). Protein abundance in
each fraction was assessed using the Bradford Assay (BioRad,
Hercules, CA).
2.3. Immunological techniques and quantiﬁcation
A polyclonal antibody recognizing the C-terminus of ACF [27] was
used for the assessment of ACF abundance, while monoclonal
antibodies recognizing either β-actin or histone H1 were used for
normalization of protein input from the cytoplasmic or nuclear
extracts (respectively). To assess total ACF, 40 μg of sample per lane
were resolved on SDS-PAGE and western blots were sequentially
probed for ACF and β-actin then visualized using ECL (Perkin Elmer
Life Sciences, Waltham, MA). Non-saturated ﬁlm exposures were
scanned and the intensity of signal quantiﬁed using ImageJ (NIH)
software. Total ACF in each fractionwas determined as a relative value
by calculating the ratio of the whole cell ACF western blot signal to
that of β-actin. The ACF/β-actin ratio for control lean animals was set
to 1 in order to evaluate changes in ACF abundance that may have
occurred in the experimental conditions.
The calculations used in quantifying ACF nuclear and cytoplasmic
distributions have been reported [17]. Brieﬂy, to calculate the
subcellular distribution of ACF, densitometric scans of ACF western
blots of cytoplasmic and nuclear extracts were normalized for β-
actin and histone H1 signals and mathematically corrected to total
amount of protein recovered in each extract. These values were
expressed as the nuclear to cytoplasmic ratio (Supplemental, Table
S1). To assess the cytoplasmic and nuclear distribution of ACF
protein was quantiﬁed using the BioRad assay kit (BioRad
Laboratories, CA) and 120 μg or 40 μg of extract (respectively)
were resolved by SDS-PAGE and probed sequentially for ACF, β-
actin and H1. The ACF western signal was normalized by dividing
the ACF signals by β-actin or histone H1 signals in the cytoplasmic
and nuclear lanes, respectively. A relative N:C ratio was then
calculated by dividing the corrected ACF band density from the
nuclear lane by the corrected ACF band density in the cytoplasmic
lane. The fold-change in ACF N:C ratio from that seen in the control
animals was calculated by dividing the N:C ratio calculated for the
insulin-treated animal by the N:C ratio of the saline-treated animal.
Reported averages are from two trials.
2.4. ApoB quantiﬁcation
For western blotting, equivalent μg amounts of cytoplasmic extract
from Ob/Ob and C57bl/6J mice were probed with an antibody
recognizing the N-terminus of ApoB (Santa Cruz Biotechnology, Santa
Cruz, CA) to assess the relative abundance of intracellular ApoB100
and ApoB48 proteins. For radioimmunoassay (RIA) assessment of
ApoB, media was replaced at 24 post-infection of rat primary
hepatocytes infected with virus expressing RNAi against acf. Media
was harvested 24 h following replacement and assessed by a
quantitative RIA using a mouse monoclonal antibody raised against
the N-terminus of rat ApoB [32]. ApoB secretionwas calibrated using a
standard curve prepared from rat VLDL. In addition, ApoB secreted in
the media, as well as intracellular ApoB in whole cell lysates was
quantiﬁed following 5 h drug treatment of primary hepatocytes with
at 5 μM Cantharidin. Cellular and media ApoB were normalized to
whole cell protein content and results were reported as ng ApoB/mg
cell protein as described above.
2.5. In vivo phosphorylation
In vivo 32Pi labeling was performed by intraperitoneal injection of
mice with 0.2 mCi/g BW of orthophosphoric acid (NEN, Boston, MA)
buffered with 50 mMHEPES, pH 7.0 and 150 mMNaCl. After 4 h, mice
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2.6. RNA analyses
Total hepatic abundance of editosome component (acf, apoB and
apobec-1) mRNAs in each mouse model was determined, using RNA
isolated from 100 mg of fresh tissue homogenized in TRI-Reagent
(MRC, Cincinnati, OH) as per manufacturer's instructions. cDNA was
prepared by ampliﬁcation of 2 μg of RNA primed by oligo dT and
ampliﬁed using real time PCR. Real time reactions were monitored
using TaqMan® (ABI, Foster City, CA) master mix with Exiqon
mouse probes 60, 40, 59, 42, 26, 69 and 43 for apobec-1, apoB, acf,
cugbp2, hnrnpa1, gryrbp and β-actin, respectively, and using the
following primers: apobec-1, ACCTTCAGCTAACCTTCACACAGT and
CGGACTTTGTTTCCTCAGGT; apoB, CCAGACAACCTCTTCCTAAAGACT
and TCAATGTTTATTTTGTTCCTGTTCA; acf, TTTGCCTTTGTGGAATAT-
GAGA and GGATGTCCCCACAACTGAAT; cugbp2, CACTGCCCACTTTG-
T A C A G C a n d A G A G G T T T G C C C C C T C T G ; h n r n p a 1 ,
GCTTTGGCGGTGGTAGTG and GCCCAAAATTGGAAGACTGA; gryrbp,
GGGGACCAAAGTAGCAGACTC and TGTAGCCTGTTCTTTCCAAAAGT;
and β-actin, AAGGCCAACCGTGAAAAGAT and GTGGTACGACCA-
GAGGCATAC. Primers designed for apoB annealed at nucleotides
3847–3870 and 3893–3917 for left and right primers, respectively,
in the 3′ end of the transcript. Rat samples assessed by real time PCR
used rat Exiqon probe numbers 70 and 18 for apoB and actin,
respectively, and cDNA was ampliﬁed with the following primers:
apoB, TCAATGTGAAGTATAACGAAGATGG and ATGTCCAGAT-
GAGCCTCTCC; β-actin, CCCGCGAGTACAACCTTCT and CGTCATC-
CATGGCGAACT. Real time reactions were run on Applied
Biosystems 7900HT Sequence Detection System cycler in 384 well
format using cycling conditions: 95 °C 10 min followed by 40 cycles
of 95 °C for 15 s and 60 °C for 1 min, and were analyzed using
Applied Biosystems SDS2.2 software.
For evaluating the effect of hormone ormetabolic treatment on the
abundance ofmRNAs encoding editosome components, 60 mmdishes
of primary hepatocytes were rinsed twice in 1× PBS then harvested by
scraping into TRI-Reagent (MRC). Two micrograms of RNA were used
to amplify cDNA input for real time PCR. Subcellular fractionation of
whole liver was carried out as described above with equivalent
portions of cytoplasmic and nuclear extracts placed in TRI-Reagent
(MRC) for assessment of compartmental apoB abundance in Ob/Ob
mice. Subcellular fractionation of primary rat hepatocytes following
cantharidin treatment was carried out as described above. Total RNA
recovered from the extractionwas poly A puriﬁed usingMicroPoly (A)
Pursuit (Ambion, Austin, TX) and 150 ng were used as input for cDNA
reaction to be used for real time PCR. β-actin was used to normalize
for input in real time PCRs.
ApoB mRNA editing was quantiﬁed by the poisoned primer
extension assay as previously described [33] on apoB cDNA ampliﬁed
from 2 μg of total RNA isolated from the liver of Ob/Ob and C57Bl/6J
mice as described above.
2.7. Treatments of primary hepatocytes
All hepatocytes were prepared as previously described and
allowed to equilibrate overnight in fresh media [14]. Hormones
used to treat mouse primary hepatocytes were: leptin, TNFα, IL-6, and
resistin, purchased from R&D systems (Minneapolis, MN) and the
doses used in each treatment were based on recommended EC50
concentrations by the manufacturer: 0.01 ng/mL, 0.05 ng/mL,
0.02 ng/mL and 10 μg/mL, respectively. Hourly treatments for 4 h at
the suggested EC50, as well as 10-fold above and below the EC50 were
tested. Resistin was only used at the provided EC50. Equal volumes of
PBS were added as control treatments. Free fatty acid treatment wascarried out for a period of 4 h at two concentrations, 0.1 and 1 mM
using a 2:1 ratio of oleate to palmitate [34].
2.8. RNAi constructs and treatment
Three non-conserved 22 nucleotide sequences were selected as
targets of acf message, GenBank Accession Number NM_133400.1,
using the RNAi Codex server at http://codex.cshl.edu. Perspective




TATTACAAATGCATAGCCTCT GTTTGCCTACTGCCTCGGA and W2,
TGCTGTTGACAGTGAGCGAAATCCTGTAC GTAAGGAACCTTTAGT-
GAAGCCACAGATGTAAAGGTTCCTTACGTACAGGATTTTGCCTACT
GCCTCGGA containing the selected targets and mir-30 sequence
context, including the hairpin loop structure, as previously described
[35] using the primers 5′ CAGAAGGGGATCCAAGGTATA TTGCTGTTGA-
CAGTGAGCG and 3′ CTAAAGTAGCCCCTTAAGCTTCCGAGGCAG-
TAGGCA. A nonspeciﬁc control sequence NS, TGCTGTTGACAGTGAG
CGATCTC GCTTGGGCGAGAGTAAGTAGTGAAGCCACAGATGTACT-
TACTCTCGCCCAAGCGAGATTGCCTACTGCCTCGGA also was ampliﬁed.
The resulting PCR products were cloned individually into pAd
shRNAmU6 vector [36] using BamHI and HindIII restriction sites.
Resulting vectors were recombined with pAdEasy-1 in the BJ5183-
AD-1 E. coli strain and infective virus produced as per manufacturer's
instructions using the pAdEasy XL Adenoviral Vector System
(Stratagene, La Jolla, CA). McArdle cells at 80% conﬂuence were
treated with 10 μL of virus for 2 h in minimal media before replacing
themedia. Infectivity wasmonitored by ﬂuorescencemicroscopy 24 h
post-infection prior to preparing whole cell lysates using Reporter
Lysis Buffer (Promega, Madison, WI) per manufacture protocol.
Primary rat hepatocytes were plated as previously described, treated
with 30 μL of virus for 2 h in minimal media and then incubated with
fresh media. Infectivity and harvest were conducted as described for
McArdle cells at 48 h post-infection.
3. Results
3.1. Dysregulation of ACF in the genetically obese and insulin-resistant
Ob/Ob mouse
Given that the normal hepatic response to insulin was to retain ACF
in the nucleus, we evaluated whether this response was retained in
insulin-resistant mice. We examined this question in the leptin-
deﬁcient Ob/Ob mice, a model for obesity-induced insulin resistance.
In Ob/Ob mice, hyperphagia, due to a lack of functional leptin, begins
from birth and is responsible for the obese phenotype and leads to
insulin resistance in adult animals [37]. Ob/Obmiceweredetermined to
be obese and diabetic, averaging twice the body weight of cogenic lean
controls (40.1 g vs. 21.4 g) and characteristic of insulin resistance, these
mice had blood glucose levels approximately 2-fold higher than
observed in lean mice (372±70mg/dL vs. 182±30mg/dL).
Using real time PCR, we examined the expression of hepatic acf,
apobec-1 and apoB mRNAs using β-actin mRNA as a normalization
control. While both apobec-1 and apoBmRNA appeared to be slightly
more abundant in Ob/Ob mouse liver relative to cogenic lean control
mice (normalized to β-actin mRNA abundance), these changes were
not statistically signiﬁcant with p≤0.29 and p≤0.17, respectively
(Fig. 1A). Unexpectedly, the abundance of acf message was increased
nearly 7-fold (p≤0.05) in Ob/Ob mouse liver. By western blotting,
Ob/Ob total hepatic ACF protein abundance was increased approx-
imately 5-fold (p≤0.01) relative to the abundance of hepatic ACF
protein in lean control mice (normalized to β-actin protein abun-
dance) (Fig. 1B). Previous studies showed that CUGBP2 [12,38] and
GRYRBP [39,40] and hnRNPA1 [40] are RNA-binding proteins that
Fig. 1. Increased ACFmRNA and protein expression in Ob/Ob liver. A. The abundance of Ob/Ob hepatic apoB, apobec-1 and acfmRNA relative to that quantiﬁed from lean control liver
was assessed by real time PCR and normalized to β-actin mRNA. Lean animal values were set to 1. Results and standard deviations were the average of the analysis of 3 livers and
statistical signiﬁcance was calculated using a Student's t-test. B. Graphic representation of total hepatic ACF protein abundance normalized to β-actin. Scanning densitometry of
western blots probed for ACF and β-actin using ImageJ (NIH) was used to create an ACF to β-actin ratio. For lean animals this ratio was set to one. A representative western blot of ACF
and β-actin is shown below the graph. The results are representative of 3 liver preparations and statistical signiﬁcance was calculated using a Student's t-test.
Fig. 2. Acute leptin treatment suppresses acfmRNA abundance. The relative abundance
of acf mRNA in primary mouse hepatocytes, normalized to β-actin mRNA abundance
was determined by real time PCR following 4 h of treatment with increasing
concentrations of leptin. Control acf mRNA to β-actin mRNA ratio was set to one.
Reduction in acfmRNA to β-actinmRNA ratios at both 1 and 10 ng/mL leptin treatment
were statistically signiﬁcant (p≤0.05 and n=3, where n is the average of one treated
60 mm plate of hepatocytes).
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with apoB mRNA and ACF inhibit apoB mRNA editing. We evaluated
whether the mRNAs encoding these proteins also were up-regulated
in Ob/Obmouse liver. Real time PCR showed that while cugbp2mRNA
was slightly elevated (1.7-fold, p≤0.4) relative to that quantiﬁed in
lean controls, the abundance of hnrnpa1 and gryrbp mRNAs were not
altered (Supplemental Fig. S1). The data suggested that there was a
signiﬁcant difference in themagnitude of up-regulation seenwith ACF
in Ob/Ob liver compared with other RNA-binding proteins we
evaluated. We therefore focused on ACF for the remainder of this
study.
To determine what was responsible for the elevated expression of
ACF mRNA and protein, we considered that the Ob/Ob mice lacked
leptin and that this may have indirectly or directly contributed to our
ﬁndings. In addition to leptin however, obesity is associated with
increased levels of other hormones such as the adipokine resistin and
pro-inﬂammatory cytokines Il-6 and TNFα [41–43]. To evaluate the
effect of these factors on acf mRNA expression under deﬁned in vitro
conditions, primary hepatocytes from lean mice were treated with
either resistin, Il-6, TNFα or free fatty acids [34,44]. All of these
treatments failed tomodulate acfmRNA abundance (data not shown).
However, treatment of primary hepatocyteswith leptin demonstrated
a dose-dependent suppression of acf mRNA (p≤0.05) (Fig. 2).
Consequently, the ability of leptin to alter acf mRNA abundance was
unique to the agents we tested. Although ACF protein levels were not
signiﬁcantly suppressed by leptin during this 4 h time course (data
not shown), our ﬁndings are consistent with the possibility that the
absence of leptin during the lifespan of the Ob/Ob mouse contributed
to the over expression of ACF. However, these data did not rule out the
possibility that insulin resistance in the Ob/Ob mouse liver also may
have contributed to the observed changes in ACF abundance.
To further explore the potential suppressive effects of leptin on acf
mRNA we quantiﬁed acf, apoB and apobec-1mRNAs in the livers from
the Db/Db genetic mouse model for obesity-induced insulin resis-
tance. In thesemice, leptin is expressed, but knockout of the long form
of the leptin receptor (Ob-Rb), expressed primarily in the brain,
induces hyperphagia leading to obesity and insulin resistance.
Important to this study, despite knockout of Ob-Rb, leptin signaling
in the liver is intact due to a short form of the leptin receptor (Ob-Ra)
expressed in the liver [45,46]. Both apoB and apobec-1 mRNAs weresuppressed in Db/Db liver to statistically signiﬁcant levels relative to
that in the livers of cogenic littermates (p≤0.01 and p≤0.05,
respectively). However, acf mRNA levels were not signiﬁcantly
different from that seen in control livers (Supplemental Fig. S2, left
panel). Total ACF protein levels in the Db/Db mouse liver also were
not signiﬁcantly different from that quantiﬁed in control animals
(Supplemental Fig. S2, right panel). The data suggested that leptin
signaling in Db/Db and lean control mouse liver maintained
comparable levels of ACF mRNA and protein expression. Taken
together, these ﬁndings supported a novel role for leptin in regulating
hepatic ACF abundance but that insulin resistance did not make a
signiﬁcant contribution to the regulation of ACF abundance.
3.2. ACF trafﬁcking defect in Ob/Ob mouse liver
Given the large increase in ACF expression in the liver of Ob/Ob
mice together with their insulin resistance, it was unclear whether
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of ACF nuclear retention. Prior to liver harvest and subcellular
fractionation, animals were fasted and received either control saline
or 1.5 IU insulin/kg body weight by intraperitoneal injection to
promote ACF's nuclear retention. Consistent with previous published
ﬁndings in rats [25], fasting of control mice resulted in a marked
increase in the proportion of total cellular ACF in the cytoplasm and
insulin treatment produced a 4-fold increase in nuclear ACF
abundance within 4 h following injection (Fig. 3A and relevant
quantiﬁcation in Supplemental Table S1). The calculated proportion
of ACF that trafﬁcs in response to insulin represents only a small
fraction of the total cellular ACF. Nonetheless, these data demonstrat-
ed that the previously characterized insulin-dependent nuclear
retention of ACF in rats [17,25] was conserved in mice.
In contrast to the lean control mice, Ob/Ob hepatic ACF was not
responsive to fasting. ACF failed to redistribute to the cytoplasm
(Fig. 3A). Moreover, insulin administration did not promote nuclear
accumulation of ACF in Ob/Ob mouse liver as evidenced by the
calculated ‘no difference’ (1-fold) in the relative nuclear to cytoplas-
mic ratio of ACF in insulin-treated versus saline-treated animals
(Fig. 3A). Similar analyses were conducted using Db/Db animals to
evaluate whether these animals also lacked an insulin response in ACF
trafﬁcking in the absence of the ACF over expression observed in Ob/
Obmice. Insulin injection did not stimulate nuclear retention of ACF in
Db/Dbmice (Fig. 3B) suggesting that the lack of a robust responsewas
a general characteristic of the obesity-induced insulin-resistant state
and was not simply due to ACF over expression characteristic of Ob/
Ob mice.
3.3. ApoB mRNA editing is resistant to insulin stimulation in Ob/Ob liver
Our laboratory [17,25] and others [15,47] have shown that apoB
mRNA editing is stimulated by insulin. Given that Ob/Ob mice are
hyperinsulinemic [48] we had anticipated a greater amount of nuclear
retention of hepatic ACF. Because this was not observed, we questioned
whether editing activity itself had become insulin-resistant. The
proportion of total hepatic apoB mRNA edited in fed Ob/Ob and Db/
Db mice was quantiﬁed by the poisoned primer extension assay
(Fig. 4A). Ob/Ob and Db/Db liver editing was 67%+/−3% (n=3) and
56%+/−5% (n=3) respectively and therefore lower than that
quantiﬁed in fed lean control animals 73%+/−1%. These ﬁndings
suggested that apoB mRNA editing was not responsive to the elevated
insulin levels that were present in fed obese mice.
We have previously shown that elevated insulin levels correlated
with an enhanced abundance of phosphoACF in the nucleus of
hepatocytes [27]. To evaluate whether Ob/Ob hepatocytes retainedFig. 3. Ob/Ob and Db/Db mouse hepatic ACF does not accumulate in the nucleus following
injected intraperitoneally with 1.5 IU insulin or saline 4 h prior to harvesting liver for e
cytoplasmic extracts of which 40 and 120 μg (respectively) were resolved by SDS-PAGE an
antibody and for β-actin and histone H1 as fraction-speciﬁc loading controls for the cytoplas
calculated as described in Materials and methods and Supplemental Table 1. The fold-change
relative N:C ratio measured in saline-treated mice). The calculations are the average of twothe ability to phosphorylate ACF, hepatic extracts were prepared from
fed control and Ob/Ob mice that had been injected intraperitoneally
with 32Pi. Nuclear and cytoplasmic extracts were immunoprecipitated
with the C-terminal ACF polyclonal antibody and the ACF recovered
analyzed by SDS-PAGE and autoradiographed. ACF was determined to
be phosphorylated and phosphoACFwas properly compartmentalized
to the nucleus in both lean controls and Ob/Ob mouse livers (Fig. 4B).
Quantiﬁcation of the 32P signal recovered with nuclear ACF per μg of
protein suggested that Ob/Ob nuclear ACF had twice the speciﬁc
labeling of ACF compared to lean control ACF (Fig. 4C). Although
phosphorylation of ACF is not required for apoB mRNA binding
[27,28], the apparent stimulation of nuclear ACF phosphorylation
without a commensurate stimulation in apoBmRNA editing suggested
that some insulin regulation of protein kinase C activity on ACF
remained intact but that editosome assembly and/or activity was
insulin-resistant in the Ob/Ob hepatocyte. The data suggest an
uncoupling of the previously observed role of ACF phosphorylation
in the stimulation of apoB mRNA editing.
3.4. Increased cytoplasmic ACF correlates with increased cytoplasmic
apoB mRNA and enhanced cytoplasmic ApoB protein
Given the localization of cytoplasmic ACF to the exterior surface of
the endoplasmic reticulum (ER), enhanced ACF expression may have
facilitated apoBmRNA translation. To evaluate whether the enhanced
cytoplasmic levels of ACF had an impact on apoB mRNA, poly A+
mRNA was isolated from nuclear and cytoplasmic extracts of Ob/Ob
and C57Bl/6J mice and apoB and β-actin sequences ampliﬁed by real
time PCR ampliﬁcation. Despite the ﬁnding that total hepatic cellular
apoBmRNA was not signiﬁcantly increased in Ob/Ob mice relative to
lean control mice (Fig. 1), a 2.5-fold increase (p≤0.01) in cytoplasmic
apoB mRNA abundance was observed in Ob/Ob mice relative to that
quantiﬁed in the cytoplasm of lean controls (Fig. 5A). The result was
commensurate with a reduction in the relative abundance of nuclear
apoB mRNA (p≤0.01) in Ob/Ob animals (Fig. 5A). Interestingly,
within hepatic cytoplasmic extracts of both mice and rats, ACF was
localized to the low density microsomal fraction (LDM) (Supplemen-
tary Fig. S3). This cytoplasmic fraction in rat hepatocytes has been
described to contain approximately 75% of cytoplasmic apoBmessage
and apoB translation complexes [31]. Cytoplasmic ACF in the Ob/Ob
mice was recovered in both LDM and high density microsomal (HDM)
fractions suggesting that a preponderance of ACF that is over
expressed in Ob/Ob mice may retain its association with apoB
mRNA in the cytoplasm.
From these data we predicted that elevated ACF in the LDM
fraction in Ob/Ob livers may stabilize apoB mRNA translationinsulin administration. Ob/Ob (A) and Db/Db (B) mice were fasted for 12 h and then
xtract preparation. Subcellular fractionation was performed to generate nuclear and
d transferred to nitrocellulose. Western blots were probed with ACF peptide-speciﬁc
m and nucleus (respectively). The nuclear to cytoplasmic ratio (N:C) of ACF signal was
in N:C ratio was calculated (as the relative N:C ratio insulin-treated mice divided by the
trials.
Fig. 4. ACF phosphorylation and apoB editing are uncoupled in Ob/Ob mice. A. ApoBmRNA was ampliﬁed from 2 μg of total RNA and apoBmRNA editing efﬁciency was evaluated by
poisoned primer extension as previously described [50]. Shown is the editing activity in the liver of three different animals. The percent editing activity is the average of the editing
activity determined in each animal and was calculated as a quotient of the signal from the primer extension product of edited apoB mRNA divided by the signals from primer
extension products from the edited and unedited mRNAs multiplied by 100. B. Fed mice were injected with 32Pi buffered orthophosphoric acid 4 h prior to liver harvest and
subcellular fractionation. Cytoplasmic and nuclear extracts were immunoprecipitated with ACF C-terminal speciﬁc polyclonal antibody, resolved by SDS-PAGE, transferred to PVDF
membrane and autoradiographed. C. The speciﬁc activity of ACF was calculated as the PhosphorImager quantiﬁed 32P signal divided by ACF western signal. The calculated speciﬁc
activity and error are the average of a determination performed on an extract from each of three animals.
Fig. 5. Enhanced ACF abundance supports increases in intracellular ApoB protein. A. Real time PCR was performed on poly A+ puriﬁed RNA from cytoplasmic and nuclear subcellular
extracts ofOb/Obandcogenic control animal liver.β-actinmRNAwasquantiﬁedasanormalization control forRNA input. The relativenuclear and cytoplasmic abundance of apoBmRNAin
controlmicewas set to one. The statistical signiﬁcancewas determined to bep≤0.01 for both cytoplasmicandnuclear differencesusing a Student's t-testwithn=3.B.Hepatic cytoplasmic
extracts from 3 different lean and Ob/Ob mice were resolved by SDS-PAGE on 5% gels and probed by western blotting using an anti-ApoB antibody reactive with the N-terminus.
Arrowheads denote the position of both ApoB100 and ApoB48. C. Total protein abundance from ‘B’ represented graphically. Statistical signiﬁcance was calculated using a Student's t-test
(n=3).
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ApoB48 from edited apoBmRNAmight be enhanced due to the ability
of the additional ACF to more effectively protect edited mRNA from
NMD [29]. Analysis of the western blots of cytoplasmic fractions
revealed a 60% increase in total ApoB (p≤0.07) (Fig. 5D) with the
majority of the increase in the abundance of ApoB48 (increased 2-fold
in Ob/Ob animal p≤0.01) (Fig. 5C). These ﬁndings are a strong
support for our hypothesis that alterations in the regulation of ACF can
affect downstream pathways involved in ApoB protein expression.3.5. ACF localization affects ApoB secretion
Our hypothesis predicts that nuclear export of ACF could affect
apoB mRNA nuclear export to the cytoplasm and its translation. To
further assess this prediction we returned to our previously
characterized nuclear retention of ACF in rat primary hepatocytes
treated with cantharidin to inhibit PP1 [27]. Cantharidin treatments of
primary rat hepatocytes at 5 μM, 10 times the IC50 of PP1, resulted in a
marked increase in nuclear ACF, coordinate with a reduction of
cytoplasmic ACF (Fig. 6A). In parallel, intracellular and secreted ApoB
protein were assessed by radioimmunoassay [32] and normalized for
protein input. A reduction in both intracellular (p≤0.02) and secreted
(p≤0.001) ApoB was observed relative to DMSO control treatment
(Fig. 6B). While the most robust inhibition was observed in ApoB
secretion, the reduction of intracellular ApoB was also signiﬁcant. TheFig. 6. Nuclear retention of ACF results in nuclear retention of apoB mRNA and a reduction
between the cytoplasm and nucleus following treatment with 5.0 μMcantharidin (10 times th
intracellular ApoB protein (ng) per mg of total intracellular protein (open bars) and secret
treatment of primary rat hepatocytes with cantharidin as in A. ApoB protein was assessed by
(for intracellular) or 8 (for secreted). C. Real time PCR was used to assess the relative abundan
treatment as in parts A and B. The results are representative of 3 trials and statistical signiﬁdata suggested a requirement for PP1 activity for proper packaging
and secretion of nascent ApoB VLDL as well as the possibility that PP1
activity may have been a requirement for the translation or stability of
ApoB itself. Real time PCR demonstrated that while apoB mRNA was
slightly elevated in the cytoplasmic fraction of cantharidin treated
hepatocytes the result was not statistically signiﬁcant (p≤0.32)
(Fig. 6C). However, the ∼2-fold increase in the nuclear abundance of
apoB mRNA was statistically signiﬁcant (p≤0.05). These ﬁndings
supported our hypothesis that ACF nuclear export was consequential
for the amount of ApoB protein that was expressed and secreted
however we cannot discount from this experiment that cantharidin
treatmentmay have affected other processes in hepatocytes that were
also responsible for the reduction in ApoB secretion.3.6. ACF abundance affects ApoB secretion
To demonstrate that ApoB expression was indeed modulated by
ACF availability and abundance, an RNAi knockdown analysis was
conducted in rat primary hepatocytes. Constructs were developed in
the pAdEasy system to target rat acf mRNA. Each of three
adenoviruses targeting one of 3 unique sites within acf mRNA were
assessed inMcArdle cells, a rat hepatic cell line, for their efﬁcacy along
with virus encoding a nonspeciﬁc and random sequence as a control
‘NS’ (Fig. 7A). The target site designated ‘H2’ resulted in the most
efﬁcient reduction of ACF protein and was subsequently used inof intracellular and secreted ApoB protein. A. Western blot analysis of ACF distribution
e IC50 of PP1) or the solvent, DMSO, used for dissolving the compound. B. The amount of
ed ApoB protein per mg total protein in the media (closed bars), are shown following
RIA as previously described. Results and standard deviations are reported where n=5
ce of apoBmRNA in the cytoplasm and nucleus, normalized to β-actin, with cantharidin
cance was calculated using a Student's t-test.
Fig. 7. Reduction of ACF abundance results in reduced ApoB protein secretion. A.Western
blot analysis of McArdle whole cell lysates resolved by SDS-PAGE 48 h after infection with
virally expressed shRNAi against acf (W2, H2, H3) or scrambled sequence (NS). NV
represents uninfected cells. Blots were probed sequentially for ACF, using antibody
recognizing the C-terminus of ACF and β-actin, using monoclonal antibody (Sigma-
Aldrich). Results are representative of duplicate experiments. B. Western blot analysis of
whole cell protein from primary rat hepatocytes with increasing MOI (Multiplicity of
Infection) of adenovirus shRNAi targeting acf, denoted H2. Blots were probed as described
in A. The abundance of ACF with NS treatment is shown at the highest MOI. Results are
representative of duplicate experiments. C. ApoB protein secreted from primary rat
hepatocytes was assessed by radioimmunoassay as previously described [32]. Media
samples were taken 48 h following infection at the maximal MOI in panel B. Results are
depicted graphically as the average nanograms of ApoB secreted for two trials.
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dependent reduction of ACF protein (Fig. 7B). NS was without effect
on ACF abundance. Infectivity was nearly 100% at the maximal MOI as
assessed by ﬂuorescence microscopy visualizing GFP expression
expressed off a CMV promoter 3′ to the shRNAi (data not shown).
The abundance of secreted ApoB protein was evaluated by RIA in
media harvested 48 h following infection of primary hepatocyte
cultures. H2 expression induced approximately 40% reduction of
secreted ApoB protein compared to cells expressing NS (Fig. 7C).
These ﬁndings are signiﬁcant in light of the foregoing experiments as
they underscore the possibility that hepatic ACF participates at an
early stage in the regulation of apoBmRNA availability for translation
in the cytoplasm.4. Discussion
In this report we describe a novel role for ACF in the regulation of
apoB mRNA export from the nucleus and the importance of this
process in animal models for modulating the expression of ApoB
protein. The function of ACF to date has been limited to its role as an
auxiliary factor required for apoB mRNA editing in mammalian small
intestine and in the liver of many species [49]. Our new ﬁndings
provide an intriguing potential hypothesis for why ACF expression has
been retained in human and nonhuman primate livers despite the loss
of APOBEC-1 expression and lack of apoB mRNA editing activity [49].
An important implication of the ﬁndings from this study was that
ACF may function early in the regulatory pathways that control
lipoprotein synthesis. Prior to our study, research on ACF focused on
its role in apoB mRNA editing [50] and studies of ApoB focused on
lipoprotein assembly and secretion [51]. Early work from this lab
showed that ACF trafﬁcking was regulated by insulin-dependent
serine phosphorylation [27,28]. We reasoned that Ob/Ob mice might
enable an evaluation of ACF trafﬁcking and ApoB expression in the
context of an insulin-resistant disease model. We observed that the
levels of hepatic acf message and protein were markedly increased.
This change stood out for the magnitude of change in acfmRNA levels
relative to that of related RNA-binding proteins.
The progression to obesity in Ob/Ob mice begins immediately
after birth due to hyperphagia. This manifests in an increased
abundance of adipose tissue, altered response to insulin stimulationand exposure of the liver to increased levels of serum insulin,
adipokines (leptin [42] and resistin [43]), pro-inﬂammatory cytokines
(Il-6 and TNFα [41]), and free fatty acid ﬂux [44]. In testing several of
these factors individually, under the deﬁned conditions of primary
hepatocyte culture, we found that only leptin had the ability to alter
acf mRNA abundance, causing its suppression in a dose-dependent
manner. Supporting a role for leptin in ACF expressionwas the ﬁnding
that insulin resistance and obesity were not sufﬁcient to change ACF
expression in the Db/Db mice that retained leptin signaling in their
livers.
The regulation of ACF abundance by leptin is only the second
example of hormonal regulation of acf message. Previously, thyroid
hormone was shown to increase the abundance of ACF in neonatal
Pax8−/− mice [12]. Treatment with thyroid hormone resulted in a
mobilization of hepatic triglycerides, which the authors hypothesized
was due to increases in the proportion of ApoB48 availability [12]. It is
of interest that the PPARα agonist, ciproﬁbrate, also reduced ACF
abundance in Low Density Lipoprotein Receptor (LDLR) knockout
animals [52]. In these studies, the amount of edited apoBmRNA varied
in direct proportion with ACF abundance. In contrast, we observed no
signiﬁcant changes in the basal level of apoB mRNA editing in Ob/Ob
mice relative to that of the lean control. These ﬁndings together with
the data showing that Ob/Ob hepatocytes failed to up-regulate ACF
retention in the nucleus underscore the importance of insulin for
controlling the function of ACF in the lean physiological state.
Our studies employed two animal models for obesity. Ob/Ob mice
express leptin receptors, but do not express leptin and consequently
become hyperphagic and obese. Db/Db mice express leptin but lack
the leptin receptor in their CNS and become hyperphagic and obese.
Obesity led to insulin resistance in both animal models. We found that
hepatic ACF nuclear retention and apoB mRNA editing activity were
insulin-resistant in both animal models. Db/Db hepatic acfmRNA and
ACF protein abundances were not elevated above control whereas
Ob/Ob acfmRNA and ACF protein levels were markedly elevated. We
attribute this difference to the expression of leptin and leptin signal in
Db/Db liver but not in the Ob/Ob liver [45]. There are several splice
variants of the leptin receptor that differ in the length of their
cytoplasmic domain required for docking of Janus kinase and STAT
proteins, through which leptin signals [53,54]. Signaling through the
long form of leptin receptor (Ob-Rb) is unlikely to have contributed to
acfmRNA suppression as only the truncated leptin receptor (Ob-Ra) is
expressed [46]. The Ob-Ra receptor lacks the consensus box 1 and 2
motifs utilized for docking of Janus kinase and therefore its signaling
does not go through a STAT3 dependent pathway [55]. Signaling
through the Ob-Ra receptor has been described through MAPK
activation [55]. Functional Ob-Ra receptor signaling has been shown
through induced expression of c-fos, c-jun, and jun-B [56]. Leptin
signaling in the Db/Db liver may have remained responsive and
therefore continued to the suppression of acf mRNA abundance. The
regulatory factors that normally modulate ACF expression will be an
important area for future research.
We cannot rule out that over expression of ACF may have
compounded the defect in regulating ACF and apoB mRNA nuclear
export and ApoB translation in the Ob/Ob mouse but our data
suggested that insulin resistance was the primary reason for why ACF
nuclear retention and apoB mRNA editing activity were not elevated
above the lean control values as would have been anticipated given
the hyperinsulinemic condition in these animals. Considering that
ACF was hyper-phosphorylated on serine residues in Ob/Ob liver and
phosphoACFwas restricted in the nucleus, PKC activity on nuclear ACF
and factors determining nuclear retention must have retained a basal
level of function. However, the possibility remains that insulin
resistance involved reduced activation of PKC and/or heightened
protein phosphatase I activity. This might explain why the radioac-
tivity per μg of ACF protein in Ob/Ob nuclei was only 2-fold higher
than that observed in the lean control when an earlier study showed
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in lean mice following a 10 nm insulin injection [27].
An equally plausible explanation for our ﬁndings is that nuclear
protein kinase C activity may have become insufﬁcient for the level of
ACF phosphorylate necessary to affect nuclear restriction because this
pathwaywas less responsive to insulin. Given that apoBmRNA editing
efﬁciencywas suppressed in Ob/Ob and Db/Dbmouse liver compared
to lean control liver, our study suggested that the insulin-dependent
processes that otherwise regulate ACF assembly into editosomes may
have been compromised by the inability to restrict adequate amounts
of ACF to the nucleus.
In published studies and in this study, the bulk of total cellular ACF
was recovered with cytoplasmic extracts from whole liver or
hepatocytes [17,25]. Immuno electron microscopy showed that
cytoplasmic ACF was predominantly localized along the exterior of
the endoplasmic reticulum [25]. This is also the intracellular site of
apoB mRNA translation where microsomal triglyceride transfer
protein facilitates co-translational lipid loading onto nascent ApoB
[57,58]. Differential centrifugation of liver cytoplasmic extracts
yielded microsomal fractions in which the rough endoplasmic
reticulum (high density microsomal fraction, HDM), smooth endo-
plasmic reticulum and Golgi stacks (low density microsomal fraction,
LDM) and residual cytoplasmwere separated [59]. The bulk of nascent
ApoB protein co-fractionated with the LDM fraction [31]. Using this
protocol, we found that most of the cytoplasmic ACF was not
recovered as a soluble protein with the residual cytoplasm fraction
but rather, was enriched in the LDM and HDM factions. This
characteristic of ACF was conserved in mice and rats. In fact, despite
the high level of ACF expression in Ob/Obmouse liver, the association
of ACF with microsomes was maintained. The relative recovery of ACF
with the Ob/Ob HDM fraction compared with the LDM fraction,
suggested that there was more ACF in the HDM fraction of obese mice
compared with HDM of lean control mice. This association is
consistent with the hypothesis that ACF maintained it association
with apoBmRNA following nuclear export to the sites of ApoB protein
synthesis in the cytoplasm. The importance of ACF abundance and
trafﬁcking for ApoB production was underscored by the ﬁnding that
ApoB secretion was inhibited through RNAi knockdown of ACF. An
additional correlation between ACF trafﬁcking and ApoB synthesis
and secretion was that nuclear retention of ACF through PP1
inhibition was associated with reduced cytoplasmic apoB mRNA and
increased nuclear apoB mRNA in primary hepatocytes. Consistent
with our hypothesis, intracellular and secreted ApoB protein was
reduced in primary hepatocytes treated with cantharidin. We propose
therefore that the inability of the liver in obese animals to
appropriately regulate nuclear retention of ACF is what led to
dysregulation of ApoB.
More detailed analysis will be necessary to de-convolute the
regulation of ACF trafﬁcking in the insulin-resistant state. Future
studies will focus on developing genetic models to determine the role
of ACF nuclear and cytoplasmic trafﬁcking in mRNA export from the
nucleus and identify the signaling pathways that regulate ACF
expression and post-translational modiﬁcation. Speciﬁcally, this
study has demonstrated, using animal models of obesity, a role for
leptin signaling in the regulation of ACF expression and shown that
deﬁciencies in nuclear retention of ACF was part of the obesity-
induced, insulin-resistant phenotype. Importantly our studies sug-
gested that independent of the function ACF has in apoBmRNA editing
activity (resulting from its interaction with APOBEC-1), ACF may have
a primary function as an apoB mRNA recognition factor and
chaperone. This function suggested a new hypothesis that may
explain why ACF continues to be expressed in nonhuman primate and
human livers even though apoB mRNA editing activity is no longer
possible. It is also possible that ACF serves to chaperone other mRNAs
that are important for development and it is the loss of this function
that accounts for why ACF knockouts were not viable. It will beimportant to develop a conditional ACF knockout animal model to
address this possibility.
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